The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of the efficacy and safety of IBI319 in patients with advanced malignant tumors.
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Jianfeng Zhou
No Relationships to Disclose
 
Qing Zhou
Honoraria - AstraZeneca; Lilly; Pfizer; Roche; Sanofi
 
Huilai Zhang
No Relationships to Disclose
 
Kefeng Ding
No Relationships to Disclose
 
Jianying Zhou
No Relationships to Disclose
 
Shuyan Wang
Employment - Innovent Biologics
 
Wenting Ji
Employment - Innovent Biologics
 
Chengli Zhang
Employment - Innovent Biologics
 
Yanqi Wang
Employment - Innovent Biologics
 
Ping Ni
Employment - Innovent Biologics